Yusuke Shimakawa
Overview
Explore the profile of Yusuke Shimakawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
1288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Riches N, Henrion M, MacPherson P, Hahn C, Kachala R, Mitchell T, et al.
Lancet Glob Health
. 2025 Feb;
13(3):e447-e458.
PMID: 40021303
Background: More new infections with hepatitis B virus (HBV) occur annually in the WHO African region than in the rest of the world combined. We did a systematic review and...
2.
Njouom R, Ndiaye A, Modiyinji A, Lissock F, Vincent J, Baba M, et al.
Virology
. 2024 Dec;
602:110316.
PMID: 39626609
This study presents a retrospective assessment of the diagnostic performance of the newly developed hepatitis B core-related antigen rapid diagnostic test (HBcrAg-RDT) in detecting plasma samples with elevated hepatitis B...
3.
Ceesay A, Drammeh S, Ndow G, Jallow A, Nyang H, Bittaye B, et al.
Microorganisms
. 2024 Nov;
12(11).
PMID: 39597662
The GeneXpert HBV Viral Load test is a simplified tool to scale up screening and HBV monitoring in resource-limited settings, where HBV is endemic and where molecular techniques to quantify...
4.
Ndow G, Shimakawa Y, Leith D, Bah S, Bangura R, Mahmoud I, et al.
Lancet Gastroenterol Hepatol
. 2024 Nov;
9(12):1133-1146.
PMID: 39521002
Background: Expanding antiviral therapy to people with chronic hepatitis B virus (HBV) infection who are ineligible to receive treatment under current international criteria has been increasingly debated. Evidence to support...
5.
Takayama Y, Shimakawa Y, Matsuyama R, Chowell G, Omori R, Nagamoto T, et al.
Emerg Infect Dis
. 2024 Oct;
30(11):2343-2351.
PMID: 39447162
During the COVID-19 pandemic, widespread school closures were implemented globally based on the assumption that transmission among children in the school environment is common. However, evidence regarding secondary infection rates...
6.
Takayama Y, Shimakawa Y, Aizawa Y, Butcher C, Chibana N, Collins M, et al.
Jpn J Infect Dis
. 2024 Sep;
78(1):8-18.
PMID: 39343560
We estimated the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) immunoglobulin G (IgG) in different island groups in Okinawa. A cross-sectional serosurvey was conducted over three periods between...
7.
Lumley S, Delphin M, Mokaya J, Tan C, Martyn E, Anderson M, et al.
J Clin Virol
. 2024 Jul;
174:105716.
PMID: 39067187
No abstract available.
8.
Delamare H, Ishii-Rousseau J, Rao A, Cresta M, Vincent J, Segeral O, et al.
JHEP Rep
. 2024 Jul;
6(8):101064.
PMID: 39035070
Background & Aims: In 2020, the World Health Organization (WHO) recommended peripartum antiviral prophylaxis (PAP) for pregnant women infected with hepatitis B virus (HBV) with high viremia (≥200,000 IU/ml). Hepatitis...
9.
Lumley S, Delphin M, Mokaya J, Tan C, Martyn E, Anderson M, et al.
J Clin Virol
. 2024 Jul;
174:105711.
PMID: 38991458
Background: As nucleos/tide analogue (NA) therapy (e.g. entecavir and tenofovir) for chronic Hepatitis B virus (HBV) infection becomes more widely indicated and available, understanding drug resistance is essential. A systematic...
10.
Takayama Y, Xu Y, Shimakawa Y, Chowell G, Kozuka M, Omori R, et al.
BMC Infect Dis
. 2024 Jun;
24(1):621.
PMID: 38910239
No abstract available.